Physician profile

Maritza Brown

Nephrology (Internal Medicine) · Elmhurst, NY

NPI 1538108006

$1,342.69

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$76.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Baxter Healthcare $862.00 2021
Aurinia Pharma U.S., INC. $161.50 2021
Astrazeneca Pharmaceuticals Lp $144.36 2020-2021
Janssen Pharmaceuticals, INC $60.66 2019-2020
Ardelyx, INC. $27.76 2024 Ibsrela
Renalytix Ai, INC. $24.71 2024 Kidneyintelx Blood Collection Convenience Kit
Travere Therapeutics, INC. $24.32 2024
Amgen INC. $22.53 2019
Actelion Pharmaceuticals US, INC. $14.85 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maritza Brown

$1,342.69

in general payments reported 2019-2025

Years
2019-2024
Top company
Baxter Healthcare

https://glasscript.com/doctor/976354/maritza-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.